The WinSanTor Solution
HOPE FOR NEUROPATHY SUFFERERS
Unmet Need
Neuropathy affects nearly 1 in 15 Americans. It is one of the largest unmet medical challenges existing today, with no FDA-approved treatments outside analgesics.
Breakthrough
We are working to treat peripheral neuropathy by reversing and regenerating nerves. Our results validate the discovery of a pathway to augment nerve growth and sensory function.
Drive
Who We Are:
+ Key Opinion Leaders
+ Leading Institutional Stakeholders
+ Proven Management Team
+ World Class Advisors
Strategy
We are focused on managing global resources to accelerate the development of treatment for patients with peripheral neuropathy.
Meet June
June is an 85-year-old woman who got neuropathy from the radiation treatment for her breast cancer. She has lost feeling in her feet and experiences numbing in her calves. Like so many others, she now has to use a walker.
Recent News
May 4-10 is Peripheral Neuropathy Awareness Week. Learn what we're doing to prevent and reverse this crippling disorder: https://t.co/gPhaFhr1Ud #PeripheralNeuropathyAwareness
Today, #WorldHealthDay, we recognize and thank all health care providers for working tirelessly to keep us healthy and safe.
We are pleased to announce the launch of our crowdfunding campaign on @StartEngineLA. Visit https://t.co/aaOJYW2OBW to find out more.
Investors
WinSanTor Inc. is a private biotechnology company focused on the discovery and development of treatments for peripheral neuropathies. WinSanTor recently completed Phase 1 trials for its lead drug, WST-057, and will begin recruiting for its Phase 2 trials in Canada to treat patients with diabetic peripheral neuropathy.